Bloomberg Talks Eli Lilly CEO Dave Ricks Talks Weight Loss Drugs Success
6 snips
Dec 10, 2024 In this discussion, Dave Ricks, CEO of Eli Lilly, shares insights on the company's groundbreaking weight-loss drugs, like Zepbound and terzepatide. He elaborates on their potential in treating addictive behaviors and combating the rising global obesity crisis. Ricks highlights the need for accessible treatments and the complexities of drug manufacturing. He also reflects on his career journey and the transformative impact these medications can have on patients' lives, emphasizing the importance of sustainable health changes.
AI Snips
Chapters
Transcript
Episode notes
Weight Loss Discovery
- Eli Lilly launched the first GLP-1 medication in 2005 for diabetes.
- A patient on the drug's cover in 2006 reported weight loss as a side effect.
Drug Names and Purposes
- There's no real difference between diabetes and obesity versions of these drugs.
- Different names exist for insurance reasons.
Drug Comparison
- Eli Lilly's Mounjaro and Novo Nordisk's Wegovy are both anti-obesity drugs.
- A study found Mounjaro users lose 47% more weight, 17 more pounds after 1.5 years than Wegovy users.